



GLAND PHARMA LIMITED

January 6, 2023

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Update on proposed acquisition of Cenexi - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further to our intimation dated 29th November, 2022 regarding the proposed acquisition of 100% stake in Phixen SAS, (doing business as ‘Cenexi’ and hereinafter referred as “Cenexi”) and 3 (three) holding companies (holding approximately 6.28% shareholding in Cenexi, hereinafter referred to as “Cenexi Holding Entities”), this is to inform you that Gland Pharma International PTE. Ltd. [‘Gland Singapore’ – a Wholly Owned Subsidiary of Gland Pharma Limited (‘the Company’)] has entered into a Share Purchase Agreement on 6th January, 2023 with FPCI Sino French Midcap Fund, as the controlling seller (investment fund managed by Cathay Capital), and others (collectively, “the Sellers”) to acquire 100% stake in Cenexi and the Cenexi Holding Entities, pursuant to the terms of the Put Option Agreement (as referred to in the intimation dated 29th November 2022).

The closing of the transaction is subject to customary closing conditions and receipt of the necessary regulatory approvals.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 have been provided in the Intimation dated 29th November 2022.

The Link to access the intimation dated 29th November 2022 is
https://glandpharma.com/images/Gland_Disclosure_Exchanges%2029112022.pdf

This is for your information and records.

Yours truly,
For Gland Pharma Limited

P Sampath Kumar
Company Secretary and Compliance Officer